Market News
Stay updated with the latest market trends, earnings, and economic indicators.
Cipla Share Price Live Updates: Cipla Posts 5.46% Return in One Week
Market at Close | Bharti Airtel, Cipla lead rally as Sensex jumps 790 points, Nifty tops 23,650
The Sensex rose 790 points to close at 75,399, while the Nifty gained 277 points to settle at 23,690. The Nifty Bank index advanced 673 points to 54,129, and the Midcap index climbed 675 points to 60,840.
Top Gainers & Losers on May 14: NLC India, Cipla, Bharti Airtel, Vedanta, MCX, BSE, Berger Paints among top gainers - Mint
Top Gainers & Losers on May 14: NLC India, Cipla, Bharti Airtel, Vedanta, MCX, BSE, Berger Paints among top gainersMint
Stocks making the biggest moves midday: BSE, MCX, Cipla, Kaynes Technology, and more - financialexpress.com
Stocks making the biggest moves midday: BSE, MCX, Cipla, Kaynes Technology, and morefinancialexpress.com
cipla paytm stock market anil singhvi strategy - Zee Business
cipla paytm stock market anil singhvi strategyZee Business
Cipla shares rally 8% despite 55% YoY slump in Q4 profit. Why Citi, Nuvama, other brokerages hiked target
Cipla shares surged on Thursday, extending gains to nearly 11% in two sessions, after several brokerages turned bullish on the stock despite a weak Q4 performance. The stock hit an intraday high of Rs 1,432.10 as investors focused on future growth prospects over near-term earnings pressure.
Cipla soars 8% despite disappointing Q4; what's driving pharma stock?
Going forward Cipla's management expects to pick up momentum in FY27 and aspires $1 billion revenue from the US itself.
Cipla shares jump 7% after at least six analyst upgrades on Q4 results, outlook
JPMorgan said Cipla’s upcoming pipeline, including launches of gVentolin, gAdvair, gSymbicort and select peptide products, as key growth drivers.
Stock Picks Today: TVS Motor, Cipla, Airtel, HPCL, Kaynes Tech And More On Brokerages' Radar
Check out top stocks under brokerages' radar heading into trade today.
Cipla bets on fast-growing biosimilars market, to steadily add products: CEO
Cipla is developing a biosimilars pipeline, with plans to add 1-2 products yearly for the next five years. The drugmaker is investing in R&D, especially for developed markets, to build out a strong pipeline across respiratory, peptides as well as complex generics.
Nifty May futures trade at a premium
Dixon Technologies (India), Cipla and HDFC Bank were the top traded contracts.
Cipla Q4 profit drops 55% to Rs 555 crore; board recommends Rs 13 dividend
Cipla's fourth-quarter net profit saw a significant drop of 55 percent year-on-year. For the full financial year, the company's profit also declined. Despite these figures, key therapies and trade generics business showed strong growth. The company plans to focus on expanding its markets and developing its future pipeline. A final dividend of Rs 13 per equity share has been recommended.